Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yong Shin

Geriatric Psychiatry Pottstown, PA Medical Doctor

NPI 1881623338 CMS profile 312156

1630 E High St Bldg 4, Pottstown, PA 19464

Open in the dashboard

General payments

$29,784

1,319 records reported · program years 2019–2025

Research payments

$125

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yong Shin of Pottstown, PA is reported in the CMS Open Payments database as having received $29,784 across 1,319 general payments and $125 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Geriatric Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,003 194
2024 General $4,131 192
2023 General $3,989 207
2022 General $3,574 216
2021 General $3,621 215
2020 General $2,505 159
2019 General $1,962 136
2019 Research $125 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yong Shin
  • Geriatric Psychiatry median
  • Middle half of Geriatric Psychiatry
  • National median

In program year 2025, general payments to Yong Shin were reported at $10,003. Among 188 Geriatric Psychiatry profiles paid that year, the median was $125 and the middle half received between $52 and $515.

Show as a table
Year Yong Shin Geriatric Psychiatry median Middle half National median
2019 $1,962 $151 $47–$484 $163
2020 $2,505 $112 $30–$410 $114
2021 $3,621 $122 $35–$550 $132
2022 $3,574 $133 $54–$557 $149
2023 $3,989 $138 $61–$485 $160
2024 $4,131 $127 $51–$572 $164
2025 $10,003 $125 $52–$515 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $5,935 9 payments
  2. Janssen Pharmaceuticals, Inc $2,182 114 payments
  3. Neurocrine Biosciences, Inc. $2,129 110 payments
  4. Otsuka America Pharmaceutical, Inc. $2,070 116 payments
  5. ITI, Inc. $1,865 94 payments
  6. Teva Pharmaceuticals USA, Inc. $1,640 66 payments
  7. Vanda Pharmaceuticals Inc. $1,626 73 payments
  8. Alkermes, Inc. $1,532 69 payments
  9. Lundbeck LLC $1,387 93 payments
  10. AbbVie, Inc. $1,351 110 payments
  11. Other $8,067 465 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $23,082 1,298 payments
  2. Debt forgiveness $5,834 1 payment
  3. Education $868 20 payments
Products named General payments · program years 2019–2025
  1. Neurostar TMS Therapy System $5,861 3 payments
  2. FANAPT $1,626 73 payments
  3. INGREZZA $1,624 72 payments
  4. CAPLYTA $1,495 78 payments
  5. REXULTI $1,400 82 payments
  6. ARISTADA Cns $1,389 63 payments
  7. ARISTADA Cns $1,389 63 payments
  8. SPRAVATO $1,285 72 payments
  9. LYBALVI $1,282 58 payments
  10. INVEGA SUSTENNA $1,260 62 payments
  11. Other $19,602 1,147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Indivior Inc. $125 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

8,501

Median for Psychiatry: 574

Drug cost

$638,481

Median for Psychiatry: $27,624

Branded share of claims

16.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 49 $408,713
Spravato Esketamine Hcl Brand 14 $54,981
Vraylar Cariprazine Hcl Brand 12 $14,541
Jardiance Empagliflozin Brand 24 $14,425
Lurasidone Hcl Generic 35 $9,435
Zyprexa Olanzapine Brand 15 $9,182
Quetiapine Fumarate Generic 602 $6,954
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 12 $6,762
Divalproex Sodium Er Divalproex Sodium Brand 146 $6,046
Mirtazapine Generic 427 $4,993

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$140,898

Medicare's payments for the services billed

Medicare patients

266

Average age 69

Services billed

1,730

179 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 71%
High blood pressure 68%
Arthritis 45%
Diabetes 27%
Chronic kidney disease 26%
Ischemic heart disease 23%
COPD 21%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
$462 49 —
REXULTI
$422 — —
CAPLYTA
$371 — —
Azstarys
$222 — —
WAKIX
$216 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

1,320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Psychiatry in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record